Cargando…

The decade of exosomal long RNA species: an emerging cancer antagonist

Exosomes have emerged as a novel approach for the treatment and diagnosis of cancer after RNA content was discovered in exosomes in 2007. As important meditators of intercellular communication, exosomes have become a strong focus of investigation for researchers in the past decade, as witnessed thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ruihao, Chen, Kaddie Kwok, Zhang, Jingtao, Xiao, Bufan, Huang, Zhaohao, Ju, Cheng, Sun, Jun, Zhang, Feifei, Lv, Xiao-Bin, Huang, Guofu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861621/
https://www.ncbi.nlm.nih.gov/pubmed/29558960
http://dx.doi.org/10.1186/s12943-018-0823-z
_version_ 1783308123108278272
author Zhou, Ruihao
Chen, Kaddie Kwok
Zhang, Jingtao
Xiao, Bufan
Huang, Zhaohao
Ju, Cheng
Sun, Jun
Zhang, Feifei
Lv, Xiao-Bin
Huang, Guofu
author_facet Zhou, Ruihao
Chen, Kaddie Kwok
Zhang, Jingtao
Xiao, Bufan
Huang, Zhaohao
Ju, Cheng
Sun, Jun
Zhang, Feifei
Lv, Xiao-Bin
Huang, Guofu
author_sort Zhou, Ruihao
collection PubMed
description Exosomes have emerged as a novel approach for the treatment and diagnosis of cancer after RNA content was discovered in exosomes in 2007. As important meditators of intercellular communication, exosomes have become a strong focus of investigation for researchers in the past decade, as witnessed through the exponential increase of research on exosomes. The capability of exosomes to transfer functionally active cargo highlights their importance as promising biomarkers and diagnostic molecules, as well as prospective drug delivery systems. The accessibility of exosomes in nearly all biofluids additionally alludes to its unprecedented ability in various types of cancers due to its extensive impact on tumor formation and progression. This review analyzes the role of exosomal long RNA species, which is comprised of mRNA, lncRNA, and circRNA, in tumor formation and progression, with an emphasis on their potential as future diagnostic biomarkers and treatment vectors in cancer biology. Their alignment with the development of exosomal databases is further examined in this review, in view of the accumulation of studies published on exosomes in the past decade. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12943-018-0823-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5861621
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58616212018-03-26 The decade of exosomal long RNA species: an emerging cancer antagonist Zhou, Ruihao Chen, Kaddie Kwok Zhang, Jingtao Xiao, Bufan Huang, Zhaohao Ju, Cheng Sun, Jun Zhang, Feifei Lv, Xiao-Bin Huang, Guofu Mol Cancer Review Exosomes have emerged as a novel approach for the treatment and diagnosis of cancer after RNA content was discovered in exosomes in 2007. As important meditators of intercellular communication, exosomes have become a strong focus of investigation for researchers in the past decade, as witnessed through the exponential increase of research on exosomes. The capability of exosomes to transfer functionally active cargo highlights their importance as promising biomarkers and diagnostic molecules, as well as prospective drug delivery systems. The accessibility of exosomes in nearly all biofluids additionally alludes to its unprecedented ability in various types of cancers due to its extensive impact on tumor formation and progression. This review analyzes the role of exosomal long RNA species, which is comprised of mRNA, lncRNA, and circRNA, in tumor formation and progression, with an emphasis on their potential as future diagnostic biomarkers and treatment vectors in cancer biology. Their alignment with the development of exosomal databases is further examined in this review, in view of the accumulation of studies published on exosomes in the past decade. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12943-018-0823-z) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-20 /pmc/articles/PMC5861621/ /pubmed/29558960 http://dx.doi.org/10.1186/s12943-018-0823-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhou, Ruihao
Chen, Kaddie Kwok
Zhang, Jingtao
Xiao, Bufan
Huang, Zhaohao
Ju, Cheng
Sun, Jun
Zhang, Feifei
Lv, Xiao-Bin
Huang, Guofu
The decade of exosomal long RNA species: an emerging cancer antagonist
title The decade of exosomal long RNA species: an emerging cancer antagonist
title_full The decade of exosomal long RNA species: an emerging cancer antagonist
title_fullStr The decade of exosomal long RNA species: an emerging cancer antagonist
title_full_unstemmed The decade of exosomal long RNA species: an emerging cancer antagonist
title_short The decade of exosomal long RNA species: an emerging cancer antagonist
title_sort decade of exosomal long rna species: an emerging cancer antagonist
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861621/
https://www.ncbi.nlm.nih.gov/pubmed/29558960
http://dx.doi.org/10.1186/s12943-018-0823-z
work_keys_str_mv AT zhouruihao thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT chenkaddiekwok thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT zhangjingtao thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT xiaobufan thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT huangzhaohao thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT jucheng thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT sunjun thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT zhangfeifei thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT lvxiaobin thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT huangguofu thedecadeofexosomallongrnaspeciesanemergingcancerantagonist
AT zhouruihao decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT chenkaddiekwok decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT zhangjingtao decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT xiaobufan decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT huangzhaohao decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT jucheng decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT sunjun decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT zhangfeifei decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT lvxiaobin decadeofexosomallongrnaspeciesanemergingcancerantagonist
AT huangguofu decadeofexosomallongrnaspeciesanemergingcancerantagonist